Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza

Antiviral Therapy

Volumn 14, Issue 7, 2009, Pages 911-921

  Prabhu, Nayana ^a   Prabakaran, Mookkan ^a   Hongliang, Qian ^a   He, Fang ^a   Ho, Hui Ting ^a   Qiang, Jia ^a   Goutama, Michael ^b   Lim, Angeline Pei Chiew ^c   Hanson, Brendon J ^c   Kwang, Jimmy ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Tridel Biosciences International Pte Ltd   (Singapore)

^c DSO NATIONAL LABORATORIES   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC MONOCLONAL ANTIBODY 3B1; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLADISTICS; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNITY; INFLUENZA; INFLUENZA VIRUS A H5N1; KIDNEY CELL; LUNG PARENCHYMA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CHICKENS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PREMEDICATION; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 72249093579     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1413     Document Type: Article

References (29)

1. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209-213. (Pubitemid 38902429)
2. Puthavathana P, Auewarakul P, Charoenying PC, et al. Molecular characterization of the complete genome of human influenza H5N1 isolates from Thailand. J Gen Virol 2005; 86:423-433. (Pubitemid 40227954)
3. de Jong MD, Thnah TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672. (Pubitemid 41817715)
4. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-894.
5. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108. (Pubitemid 41509341)
6. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000; 47:57-77.
7. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
8. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006; 357:489.
9. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1451. (Pubitemid 47535608)
10. Lu J, Guo Z, Pan X, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab′)2 in mice. Respir Res 2006; 7:43.
11. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135:1530-1535. (Pubitemid 16237070)
12. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
13. Wang Y, Feng J, Huang Y, et al. The design, construction and function of a new chimeric anti-CD20 antibody. J Biotechnol 2007; 129:726-731. (Pubitemid 46590459)
14. Zebedee SL, Koduri RK, Mukherjee J, et al. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 1994; 38:1507-1514. (Pubitemid 24203560)
15. Hanson BJ, Boon AC, Lim AP, et al. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza H5 hemagglutinin in mice. Respir Res 2006; 7:126.
16. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11:1515-1521.
17. US National Institutes of Health, US Centers for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories. 4th ed. Washington: US Government Printing Office 1999.
18. World Health Organization. Laboratory biosafety manual. 3rd ed. Geneva: World Health Organization 2004.
19. Jostock T, Vanhove M, Brepoels E, et al. Rapid generation of functional human IgG antibodies derived from Fabon-phage display libraries. J Immunol Methods 2004; 289:65-80. (Pubitemid 38900905)
20. Prabakaran M, Velumani S, He F, et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008; 380:412-420.
21. Suguitan AL, Jr., McAuliffe J, Milis KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross protection in mice and ferrets. PLoS Med 2006; 3:e360.
22. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-497.
23. Kaverin NV, Rudneva IA, Ilyushina NA, et al. Structure of antigenic sites on the haemagglutinin molecule of H5 influenza virus and phenotypic variation of escape mutants. J Gen Virol 2002; 83:2497-2505.
24. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC, Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45:879-885. (Pubitemid 15161095)
25. Dall'Acqua WF, Damschroder MM, Zhang J, et al. Antibody humanization by framework shuffling. Methods 2005; 36:43-60.
26. Throsby M, Van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008; 3:e3942.
27. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-273.
28. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373-378.
29. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31:417-427. (Pubitemid 13178866)